New Crystal Forms for Cancer Treatment Bantam Pharmaceutical’s Thiazolylpyrazole Polymorphs

Bantam Pharmaceutical, LLC has filed a patent covering crystalline polymorphs of a thiazolylpyrazole compound – a class of small molecule drug candidates with potential anti-cancer activity. The invention focuses on specific solid-state crystal forms of the compound, which can significantly influence pharmaceutical properties such as solubility, stability and bioavailability.

The Problem

Drug development is a complex, multi-stage process in which identifying a biologically active compound is only the beginning. For a small molecule drug candidate to become a medicine that can be manufactured, stored, formulated and administered reliably, it must have appropriate physical and chemical properties in its solid state. Many promising drug candidates fail to progress to clinical use not because they lack biological activity, but because their physical form is poorly suited to pharmaceutical manufacturing.

Crystalline polymorphism – the existence of the same chemical compound in multiple distinct crystal structures – is a common feature of organic small molecules, including pharmaceutical compounds. Different polymorphic forms of the same compound can have dramatically different properties: some may be more soluble, some more stable, some more easily processed during manufacturing. A drug substance that crystallises predominantly in one polymorph under certain conditions but shifts to a different polymorph under other conditions creates unpredictable variability in formulation performance and may even change efficacy or safety profiles between batches.

Identifying and characterising the full set of polymorphic forms that a drug candidate can adopt, and selecting the most pharmaceutically suitable form for development, is a critical step in pharmaceutical development. For companies working on novel cancer treatments, securing intellectual property protection over specific polymorphic forms is also strategically important, since it extends the protection of the molecule beyond the base compound patent.

What This Invention Does

Bantam Pharmaceutical’s invention covers crystalline polymorphic forms of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative – a specific chemical compound within the thiazolylpyrazole class. These compounds are of interest in oncology, as reflected by the inclusion of anti-cancer activity (A61P 35/00) in the international patent classification.

The patent covers the crystalline polymorphs themselves, pharmaceutical compositions containing them, and methods of using these crystalline forms and compositions. The inclusion of methods of use indicates that the patent protects not just the material forms of the compound but also their therapeutic application – providing multi-layered protection that covers both the drug substance and the therapeutic act of administering it.

By characterising specific crystalline polymorphs, the invention provides pharmaceutical manufacturers with defined target crystal forms that offer predictable and reproducible physical properties. The specific polymorph selected for development will typically be the one that combines optimal solubility and stability – properties that directly influence how well the drug is absorbed by patients and how it survives during storage, shipping and manufacturing.

Key Features

Crystalline polymorph characterisation. The invention identifies and characterises specific crystalline polymorphic forms of the thiazolylpyrazole derivative, providing defined physical forms with distinct and predictable pharmaceutical properties.

Oncology indication. The compound is classified under A61P 35/00 (anti-cancer activity), positioning this as a potential cancer treatment and reflecting the therapeutic context in which the compound’s biological activity has been identified.

Pharmaceutical composition coverage. Beyond the pure crystalline forms, the patent covers pharmaceutical compositions containing them, extending protection to the formulated drug product as well as the active ingredient.

Methods of use protection. The inclusion of methods of use provides protection for the therapeutic application of the crystalline polymorphs, adding a layer of intellectual property coverage beyond the physical compound and formulation.

Divisional of PCT-originating application. The application traces back to a PCT international application (PCT/US2020/035343) and a US provisional application from May 2019, indicating a compound that has been in development and characterisation for several years.

Who Is Behind It?

Bantam Pharmaceutical, LLC is a US-based pharmaceutical company focused on the development of novel small molecule therapeutics. The inventors – Alan Cooper, Zheqiong Wu and Shanming Kuang – bring expertise in medicinal chemistry, crystallography and pharmaceutical development. The application is filed through AJ Park and is a divisional of AU 2020283129, the Australian national phase entry of the original PCT application. The divisional approach enables protection of specific aspects of the invention – in this case, particular crystalline forms – that may be distinct from claims protected in the parent application.

Why It Matters

Cancer remains one of the leading causes of death globally, and the development of new small molecule cancer treatments continues to be a major priority for pharmaceutical research. The thiazolylpyrazole class of compounds represents one avenue in the search for novel anti-cancer agents, and the identification of stable, well-characterised crystalline forms is a necessary step on the path from promising chemical entity to clinical drug candidate.

Polymorph patents occupy an important and sometimes controversial place in pharmaceutical intellectual property, because they can extend the effective life of protection for a compound beyond the expiry of the original molecule patent. From a pharmaceutical development perspective, however, polymorph characterisation is a genuine technical challenge that requires significant scientific investment – identifying, characterising and reliably producing specific crystal forms is not trivial, particularly for complex heterocyclic compounds. Bantam Pharmaceutical’s work in this area reflects the deep technical effort required to take a cancer drug candidate from discovery chemistry through to a product with the physical properties needed for clinical development and eventual commercial manufacture.

---

AU 2026201586 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.